Madrigal Pharmaceuticals, Inc. Share Price
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
12:08:07 04/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 541.86 USD | -0.93% |
|
-0.22% | -6.84% |
| Market Cap | 1.26TCr 1.09TCr 1.02TCr 933.47Cr 1.74TCr 1,19500Cr 1.76TCr 12TCr 4.7TCr 61TCr 4.75TCr 4.64TCr 1,96600Cr | P/E 2026 * |
-86.6x | P/E 2027 * | 86.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.21TCr 1.04TCr 977.93Cr 894.72Cr 1.67TCr 1,14500Cr 1.68TCr 12TCr 4.51TCr 59TCr 4.55TCr 4.45TCr 1,88400Cr | EV / Sales 2026 * |
7.94x | EV / Sales 2027 * | 5.45x |
| Free-Float |
94.12% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MDGL | Delayed | |
CBOE
| MDGL | Real-time | |
|
Deutsche Boerse AG
| YDO1 | Delayed | |
|
Tradegate
| YDO1 | Real-time | |
|
Börse Stuttgart
| YDO1 | Delayed | |
|
Boerse Muenchen
| YDO1 | Real-time | |
|
Borsa Italiana
| 1MDGL | End-of-day quote | |
|
Xetra
| YDO1 | Delayed |
Last Transcript : Madrigal Pharmaceuticals, Inc.
| 1 day | -0.93% | ||
| 1 week | -0.22% | ||
| Current month | +0.45% | ||
| 1 month | +12.55% | ||
| 3 months | +11.13% | ||
| 6 months | +27.39% | ||
| Current year | -6.84% |
| 1 week | 523.29 |  | 552.08 |
| 1 month | 489.23 | | 552.08 |
| Current year | 416.21 | | 598.79 |
| 1 year | 393.6 | | 615 |
| 3 years | 119.76 | | 615 |
| 5 years | 52.33 | | 615 |
| 10 years | 9.85 | | 615 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 08/09/2023 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 11/03/2024 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 21/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 01/07/2016 |
Richard Levy
BRD | Director/Board Member | 68 | 11/08/2016 |
James Daly
BRD | Director/Board Member | 64 | 27/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/08/26 | Sell | General Counsel | -664 | 0.0029% | ||
| 15/08/26 | Free | Director | 1,725 | 0.0075% | ||
| 20/07/26 | Sell | Chief Executive Officer | -2,500 | 0.0108% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93% | -0.22% | +24.63% | +194.03% | 1.26TCr | |
| +1.03% | -2.05% | +39.28% | +94.60% | 6.89TCr | |
| +1.31% | +0.55% | +49.48% | +92.12% | 6.53TCr | |
| -1.08% | +3.20% | -12.70% | +375.09% | 2.77TCr | |
| +2.97% | -0.10% | +41.86% | +14.84% | 2.58TCr | |
| -0.60% | -7.24% | +2.90% | -15.30% | 2.61TCr | |
| +1.01% | +1.38% | +26.48% | -17.50% | 2.01TCr | |
| +3.45% | -14.83% | +225.22% | +389.50% | 1.7TCr | |
| +0.77% | -4.55% | -0.36% | +549.41% | 1.5TCr | |
| +1.76% | +7.65% | +60.96% | +167.13% | 1.45TCr | |
| Average | +0.99% | -2.24% | +45.77% | +184.39% | 2.93TCr | |
| Weighted average by Cap. | +1.01% | -1.97% | +41.97% | +144.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 152.63Cr 131.32Cr 123.24Cr 112.75Cr 210.44Cr 14TCr 212.11Cr 1.46TCr 567.74Cr 7.37TCr 573.15Cr 560.65Cr 24TCr | 214.49Cr 184.55Cr 173.18Cr 158.45Cr 295.73Cr 20TCr 298.07Cr 2.05TCr 797.83Cr 10TCr 805.45Cr 787.88Cr 33TCr |
| Net income | -18Cr -16Cr -15Cr -14Cr -25Cr -1.74TCr -26Cr -175.62Cr -68Cr -888.24Cr -69Cr -68Cr -2.86TCr | 20Cr 17Cr 16Cr 15Cr 28Cr 1.89TCr 28Cr 191.02Cr 74Cr 966.15Cr 75Cr 73Cr 3.11TCr |
| Net Debt | -52Cr -45Cr -42Cr -39Cr -72Cr -4.96TCr -73Cr -500.99Cr -195.11Cr -2.53TCr -196.97Cr -192.67Cr -8.16TCr | -94Cr -81Cr -76Cr -70Cr -130.05Cr -8.92TCr -131.08Cr -900.91Cr -350.85Cr -4.56TCr -354.2Cr -346.47Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $542.48 | -0.81% | 66,439 |
| 02/26/02 | $546.93 | +1.53% | 2,02,818 |
| 01/26/01 | $538.71 | -0.24% | 1,65,754 |
| 31/26/31 | $540.03 | +1.17% | 1,34,578 |
| 28/26/28 | $533.76 | -1.83% | 2,68,664 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MDGL Stock
Select your edition
All financial news and data tailored to specific country editions
